Scienture Holdings, Inc.
Scienture Holdings, Inc. (Nasdaq: SCNX) is a specialty pharmaceutical company focused on commercializing and developing treatments for cardiovascular and central nervous system diseases. Its marketed products include Arbli, an FDA-approved liquid losartan formulation for hypertension, and REZENOPY, a 10 mg naloxone… From the company’s description.
Over the twelve months to Jun 30, 2026, Scienture Holdings, Inc. reported revenue of $0.82M, up 542.2% from a year earlier. Operations used $14.44M in cash. In fiscal 2025, it reported revenue of $0.43M, up 215.9% from fiscal 2024.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Scienture Holdings, Inc. does
In the company’s own words
Scienture Holdings, Inc. (Nasdaq: SCNX) is a specialty pharmaceutical company focused on commercializing and developing treatments for cardiovascular and central nervous system diseases. Its marketed products include Arbli, an FDA-approved liquid losartan formulation for hypertension, and REZENOPY, a 10 mg naloxone nasal spray licensed for U.S. commercialization for opioid overdose reversal. The company is also developing candidates for migraine and cluster headache, catheter occlusion, and postsurgical pain. It sells primarily through pharmaceutical wholesalers, specialty pharmacies, and distributors, which supply pharmacies, hospitals, long-term care institutions, and other customers. Scienture Holdings operates through its wholly owned subsidiary Scienture LLC, acquired in July 2024; the subsidiary began operations in 2019. It plans to market products in the United States using its own commercial resources and external sales support, while pursuing collaborations for markets outside the country. Manufacturing is outsourced to third-party contractors. In fiscal 2025, the company commercially launched Arbli and acquired the commercial-ready REZENOPY asset. Its website is www.scientureholdings.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- COMMACK, NY
- Fiscal year end
- December
- CIK
- 1382574
- SIC
- 2834
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Scienture Holdings, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Scienture Holdings, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Scienture Holdings, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Scienture Holdings, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Scienture Holdings, Inc.'s last four quarterly filings that the numbers alone won't show?”